The global fibroblast growth factor receptor inhibitor market was estimated to reach a valuation of USD 128.14 million in the year 2022. With a robust CAGR of 13.2% from 2023 to 2033, this market is expected to reach USD 145.06 million by 2023 and USD 501.2 million by 2033.
Current developments in the field of oncology's use of small molecule-based treatment have led to outstanding improvements in the survival rate of cancer patients. Fibroblast growth factor receptor inhibitors are now generally acknowledged for the treatment of a variety of cancer types, including breast cancer, bladder cancer, lung cancer, lymphoma, gastric cancer, and myeloma.
They are regarded as one of the most sophisticated anticancer therapies. The use of fibroblast growth factor receptor inhibitors has quickly overcome all obstacles and brought about a situation in which the provision of treatment is greatly valued and commended.
The majority of researchers investigating the therapeutic value of this class of molecules concluded that this strategy was effective because of the overexpression or mutation of fibroblast growth factor receptor inhibitors, which makes them a suitable target for the treatment of cancer.
Moreover, fibroblast growth factor receptor inhibitor changes are seen in uncommon tumors as well, suggesting that this strategy might be extremely important in the treatment of uncommon malignancies that are now incurable. The fibroblast growth factor receptor inhibitor market is now in its infancy and is supported by sales of the three authorized drugs in this class-
Balversa is anticipated to dominate the market sector since it is anticipated that its worth would expand dramatically following clearance in key markets like Europe as well as Japan. The market for fibroblast growth factor receptor inhibitors was expected to be worth around USD 100 million in 2020, and it was anticipated to expand at a rapid CAGR over the following few years since most market-related indicators point to this segment's increased acceptability in the near future.
The market size of this sector will increase as more new medications in this class are anticipated to receive the orphan designation in the future years. Such developments are sure to open up new opportunities for the existing players in the global market.
Region-wise, due to a significant cancer burden and top pharmaceutical companies, the US will dominate the fibroblast growth factor receptor inhibitor industry. Due to the accessibility of all the above-mentioned three medications in this class, the drug approval procedure has been streamlined in the US, and as a result, the majority of new fibroblast growth factor receptor inhibitor inhibitors will receive clearance in this country first.
Leading pharmaceutical firms are anticipated to work with CROs and regional pharmaceutical firms of developing firms to improve the market penetrability as well as commercialization of fibroblast growth factor receptor inhibitors, which will expand the market size in regions like the Middle East, Asia-Pacific, and Latin America.
Amgen, AstraZeneca, Astem Pharma, Bayer, Incyte, BMS, Roche, Janssen Pharmaceuticals, Taiho, Novartis, and other top pharmaceutical firms are operating in this market, while several more businesses are developing fibroblast growth factor receptor inhibitors in preclinical research. Such factors are anticipated to make new developments in this market during the forecast period.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | USD 145.06 million |
| Expected Market value in 2033 | USD 501.2 million |
| Growth Rate (2023 to 2033) | CAGR of 13.2% from 2023 to 2033 |
FGFR is a protein molecule found on the surface of normal cells having a binding site for its growth factor. Fibroblast Growth factors (FGF) bind to Fibroblast Growth Factor Receptors (FGFR) for cell signalling.
These are transmembrane tyrosine kinase receptors. FGFR inhibitors are drugs that decelerate or terminate FGFR’s activity. They play a pivotal role in diverse cellular processes like cell proliferation, differentiation, migration, cell metabolism, tissue homeostasis, angiogenesis and wound repair
FGFRs belong to tyrosine kinase family and are subdivided into FGFR1, FGFR2, FGFR3 and FGFR4 receptor families. Abnormal FGFR signalling has been correlated with the progression of malignancy. Inhibition of FGFR signaling arises as a promising target for developing novel therapeutics against cancer. About 15 cancer types have shown to develop because of FGFR alterations.
Around 9.6 million people worldwide have been reported to die due to cancer in 2018 according to WHO. There are two types of FGFR inhibitors: selective inhibitors that target specific FGFR and non-selective inhibitors that target all or most of FGFRs.
Amongst the four subtypes, FGFR3 is the least characterized for cancer treatment. Non -selective inhibitors used for cancer treatment include Dovitinib, Ponatinib, Brivanib, RG150, Cediranib, Vargalef and Lenvatinib.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
FGFR inhibitors are seeking intensive attention as a promising anticancer therapy. Increase in incidences of cancer across the world, lifestyle changes and ongoing research and development for novel FGFR inhibitors can be major drivers for growth of this market.
This type of targeted cancer therapy potentially targets cancer cells further attributing safety to the patients as compared to conventional chemotherapies. Increasing focus on oncological research is a major driving force for the market growth.
Institutes like National cancer Institute and others invest a lot in cancer research. Lot of research includes stem cell research and it is gaining attractiveness form researchers worldwide. Increasing in-vitro research on FGFR inhibitors and their respective pathways has helped to understand preclinical attributes of cancer and other diseases.
However, cost of the treatment, alternative therapy options and failure in efficacy during clinical trials can restrain the market growth.
Few growth factors inhibitors are extremely costly and cannot be affordable even for primary research. Also, lack of skilled scientists for research and lack of skilled professionals is a major set- back for the FGFR inhibitors market.
Despite advances in the past years, cancer continues to be one of the major causes of mortality worldwide. With the escalation of COVID-19 pandemic, the healthcare systems are affected worldwide. As valuable medical resources are diverted for addressing Covid-19 pandemic, the manufacturing process of these drugs has come to halt.
The global market for FGFR inhibitors is estimated to grow during the 2020 to 2030. The increase in incidence of cancer worldwide creates a more profitable opportunity for manufactures present in the market. At present, Erdafitinib (JNJ-42756493) is the first FDA approved drug used for therapy.
CH5183284 is into phase II/III of clinical trial. Rogaratinib is into phase I/II of clinical trial. Some nonselective inhibitors like Ponatinib, Dovitinib, Lucitanib and Nintedanib have proved to be potent towards FGFR. Most of the FGFR inhibitors currently under evaluation are typical type I inhibitors, type II inhibitors, covalent irreversible or covalent reversible inhibitors for cancer treatment.
Principal Consultant
The FGFR inhibitor market in the USA is expected to upswing because of ongoing research and development for novel targets and many drugs being in Clinical trial Phase 3. Due to increasing prevalence of cancer and other chronic diseases the market is expected to grow rapidly in North America and Europe.
Increasing healthcare expenditure by governments in developed countries can expand the market growth. Lower economic nations in Asia- Pacific and Oceania are increasing their focus on development of good healthcare facilities and patient care and thus increasing chances of FGFR inhibitor market growth.
The awareness of cancer and it treatment is also rising in developing countries. The healthcare expenditure in developing countries has got better in recent years making these economies highly adoptive for the FGFR inhibitor market.
The key participants operating in the global FGFR inhibitor market are:
The research report on FGFR inhibitor presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on FGFR inhibitor provides analysis and information according to market segments such as geographies, application, and industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global FGFR inhibitor market is segmented based on the receptor type, application in cancer type, therapy type, drug type, therapy type, drug development status, clinical trial recruitment status, end user and region.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Drugs 6.2. Therapy Type 6.3. Application In Cancer 6.4. Distribution Channel 7. Global Market Analysis and Forecast, By Drugs 7.1. Selective Inhibitors 7.2. Non-selective Inhibitors 7.3. Monoclonal Antibodies 8. Global Market Analysis and Forecast, By Therapy Type 8.1. Combination Therapy 8.2. Monotherapy 9. Global Market Analysis and Forecast, By Application In Cancer 9.1. Squamous NSCLC 9.2. Breast Cancer 9.3. Bladder Cancer 9.4. Myeloma 9.5. Cervical Cancer 9.6. Gastric Cancer 10. Global Market Analysis and Forecast, By Distribution Channel 10.1. Hospitals Pharmacies 10.2. Research Laboratories 10.3. Pharmacies 10.4. Online Pharmacies 11. Global Market Analysis and Forecast, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. Asia Pacific 11.5. China 11.6. Japan 11.7. Middle East and Africa 12. North America Sales Analysis and Forecast, by Key Segments and Countries 13. Latin America Sales Analysis and Forecast, by Key Segments and Countries 14. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 15. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 16. China Sales Analysis and Forecast, by Key Segments and Countries 17. Japan Sales Analysis and Forecast, by Key Segments and Countries 18. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 19. Sales Forecast by Drugs, Therapy Type, Application In Cancer, and Distribution Channel for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Bayer AG 21.2. Pharmaceuticals 21.3. Boehringer Ingelheim International GmbH 21.4. Novartis International AG 21.5. Bristol-Myers Squibb Company 21.6. Pfizer Inc 21.7. Incyte Corp 21.8. Blueprint Medicine Corporation 21.9. AstraZeneca 21.10. Janssen Pharmaceutica 21.11. F. Hoffmann-La Roche Ltd 21.12. Amgen Inc
Healthcare
September 2023
REP-GB-10376
250 pages
Explore Healthcare Insights
View Reports
Fibroblast Growth Factor Receptor inhibitor market
